Related Experiment Video
Updated: Sep 3, 2026
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Prevalence and Associated Factors of Metabolic Dysfunction-Associated Steatotic Liver Disease Across Obesity
Yu Ma1,2, Xinyue Chen1,2, Huachen Wang1,2
1School of Mental Health and Psychological Sciences, Anhui Medical University, Hefei, People's Republic of China.
Background:
Chronic schizophrenia patients often present with exacerbated clinical symptoms and higher rates of fatty liver disease. This study is designed to compare the occurrence rates of metabolic dysfunction-associated steatotic liver disease (MASLD) and associated factors among hospitalized chronic schizophrenia patients with different obesity metabolic phenotypes.
Methods:
In this cross-sectional study, we retrospectively analyzed a cohort of 302 chronic schizophrenia patients aged 18-70 years. Patients were classified according to their obesity status (defined as body mass index ≥28 kg/m2) and metabolic health profile, resulting in four distinct obesity metabolic phenotypes: metabolically healthy non-obese (MHNO), metabolically unhealthy non-obese (MUNO), metabolically healthy obese (MHO), and metabolically unhealthy obese (MUO). Their sociodemographic information, biochemical and lipid parameters were retrospectively collected.
Results:
In this study, we found that the occurrence rate of metabolic dysfunction-associated steatotic liver disease (MASLD) among chronic schizophrenia patients with prolonged hospitalization was 54.6%. Within the MHNO grouping, MASLD-positive and MASLD-negative subgroups showed significant differences in key metabolic indicators, diabetes status, antipsychotic polypharmacy, and triglyceride-glucose-body mass index (TyG-BMI). Logistic regression analysis demonstrated that Antipsychotic polypharmacy (OR=2.656, P=0.007, 95% CI=1.299-5.429) and TyG-BMI (OR = 1.043, P <0.001, 95% CI = 1.029-1.057) were independently associated with MASLD in the MHNO group.
Conclusion:
Metabolic dysfunction-associated steatotic liver disease is prevalent among chronic schizophrenia patients, with a notable prevalence gradient across obesity metabolic phenotypes. For metabolically healthy non-obese chronic schizophrenia patients, the importance of regular metabolic dysfunction-associated steatotic liver disease screening cannot be overlook ed.
Related Concept Videos
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:24Obesity
01:26Type II Diabetes I: Introduction
01:19Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
01:21Chronic Pancreatitis II: Pathophysiology
01:29Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.